


产品名称: Erastin

产品别名: Erastin

生物活性:																										
Description	Erastin is a ferroptosis inducer. Erastin binds and inhibits voltage-dependent anion channels (VDAC2/VDAC3).																									
In Vitro	Erastin triggers oxidative, iron-dependent cell death. Treatment of NRAS-mutant HT-1080 fibrosarcoma cells with the RSL molecule erastin (10 μM) results in a time-dependent increase in cytosolic and lipid ROS beginning at 2 hours[1]. Cell death triggered by erastin is significantly inhibited by antioxidants (e.g., α-tocopherol, butylated hydroxytoluene, and β-carotene) and iron chelators, suggesting that ROS- and iron-dependent signaling is required for erastin-induced ferroptosis. Erastin can directly bind to VDAC2/3 in BJeLR cells. Knockdown of VDAC2 and VDAC3, but not VDAC1, leads to erastin resistance. Erastin has the ability to reduce glutathione level by directly inhibiting cystine/glutamate antiporter system Xc- activity, with activation of the ER stress response[2]. Erastin potently inhibits HT-29 cell survival. Erastin shows a dose-dependent effect, and 30 μM of erastin displays the most dramatic effect[3].																									
In Vivo	Intraperitoneal injection of erastin at well-tolerated doses dramatically inhibits HT-29 xenograft growth in severe combined immunodeficient mice[3].																									
Solvent&Solubility	<p>In Vitro:</p> <p>DMSO : 20 mg/mL (36.56 mM; Need ultrasonic)</p> <p>H₂O : < 0.1 mg/mL (insoluble)</p> <table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent</th><th>Mass</th><th>Concentration</th><th></th></tr><tr><th></th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><td>1 mM</td><td>1.8280 mL</td><td>9.1401 mL</td><td>18.2802 mL</td></tr><tr><td>5 mM</td><td>0.3656 mL</td><td>1.8280 mL</td><td>3.6560 mL</td></tr><tr><td>10 mM</td><td>0.1828 mL</td><td>0.9140 mL</td><td>1.8280 mL</td></tr></tbody></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时,请在 6 个月内使用, -20°C 储存时,请在 1 个月内使用。</p> <p>In Vivo:</p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:</p> <p>——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶</p> <p>1. 请依序添加每种溶剂: 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 2 mg/mL (3.66 mM); Clear solution</p> <p>此方案可获得 ≥ 2 mg/mL (3.66 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀。向上述体系中加入 50 μL Tween-80, 混合均匀;然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2. 请依序添加每种溶剂: 10% DMSO → 90% (20% SBE-β-CD in saline)</p> <p>Solubility: 2 mg/mL (3.66 mM); Suspended solution; Need ultrasonic</p> <p>此方案可获得 2 mg/mL (3.66 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。</p>					Preparing Stock Solutions	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	1 mM	1.8280 mL	9.1401 mL	18.2802 mL	5 mM	0.3656 mL	1.8280 mL	3.6560 mL	10 mM	0.1828 mL	0.9140 mL	1.8280 mL
Preparing Stock Solutions	Solvent	Mass	Concentration																							
		1 mg	5 mg	10 mg																						
1 mM	1.8280 mL	9.1401 mL	18.2802 mL																							
5 mM	0.3656 mL	1.8280 mL	3.6560 mL																							
10 mM	0.1828 mL	0.9140 mL	1.8280 mL																							

	<p>以 1 mL 工作液为例，取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p> <p>3.请依序添加每种溶剂： 10% DMSO → 90% corn oil Solubility: ≥ 2 mg/mL (3.66 mM); Clear solution</p> <p>此方案可获得 ≥ 2 mg/mL (3.66 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p>
--	--

References	<p>[1]. Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. <i>Cell.</i> 2012 May 25;149(5):1060-72.</p> <p>[2]. Xie Y, et al. Ferroptosis: process and function. <i>Cell Death Differ.</i> 2016 Mar;23(3):369-79.</p> <p>[3]. Huo H, et al. Erastin Disrupts Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death of Colorectal Cancer Cells. <i>PLoS One.</i> 2016 May 12;11(5):e0154605.</p>
实验参考：	
Cell Assay	To test erastin's activity on colorectal cancer cell survival, HT-29 cells are treated with increasing concentrations of erastin (0.1–30 μ M). MTT assay was performed[3].
Animal Administration	Mice: Mice are treated daily with 10 or 30 mg/kg body weight of erastin (intraperitoneal injection, for 4 weeks) or vehicle control (Saline). Tumor volumes are calculated. Mice body weights are also recorded every week[3].
References	<p>[1]. Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. <i>Cell.</i> 2012 May 25;149(5):1060-72.</p> <p>[2]. Xie Y, et al. Ferroptosis: process and function. <i>Cell Death Differ.</i> 2016 Mar;23(3):369-79.</p> <p>[3]. Huo H, et al. Erastin Disrupts Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death of Colorectal Cancer Cells. <i>PLoS One.</i> 2016 May 12;11(5):e0154605.</p>



源叶生物